-
MLTX Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
MoonLake Immunotherapeutics (MLTX)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 180.43 mm | 180.43 mm | 180.43 mm | 180.43 mm | 180.43 mm | 180.43 mm |
Cash burn (monthly) | 65.08 mm | 22.56 mm | 16.53 mm | 11.92 mm | 16.16 mm | 9.72 mm |
Cash used (since last report) | 149.33 mm | 51.77 mm | 37.92 mm | 27.36 mm | 37.08 mm | 22.29 mm |
Cash remaining | 31.09 mm | 128.65 mm | 142.50 mm | 153.06 mm | 143.35 mm | 158.13 mm |
Runway (months of cash) | 0.5 | 5.7 | 8.6 | 12.8 | 8.9 | 16.3 |
13F holders | Current |
---|---|
Total holders | 116 |
Opened positions | 19 |
Closed positions | 15 |
Increased positions | 46 |
Reduced positions | 33 |
13F shares | Current |
---|---|
Total value | 3.21 tn |
Total shares | 82.97 mm |
Total puts | 92.40 k |
Total calls | 121.00 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 19.75 mm | $985.00 mm |
BVF | 19.75 mm | $1.07 tn |
Cormorant Asset Management | 8.49 mm | $459.96 bn |
FMR | 6.34 mm | $343.39 bn |
T. Rowe Price | 3.34 mm | $181.06 mm |
Avoro Capital Advisors | 2.77 mm | $150.00 bn |
Citadel Advisors | 2.19 mm | $118.42 bn |
Paradigm Biocapital Advisors | 1.77 mm | $95.97 bn |
GS The Goldman Sachs Group, Inc. | 1.67 mm | $90.68 bn |
Holocene Advisors | 1.59 mm | $85.84 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Feb 25 | Matthias Bodenstedt | Class A ordinary shares, par value $0.0001 per share | Grant | Acquire A | No | No | 0 | 95,763 | 0.00 | 616,666 |
27 Feb 25 | Kristian Reich | Stock Option Class A ordinary shares, par value $0.0001 per share | Grant | Acquire A | No | No | 41.77 | 139,273 | 5.82 mm | 139,273 |
27 Feb 25 | da Silva Jorge Santos | Class A ordinary shares, par value $0.0001 per share | Grant | Acquire A | No | No | 0 | 95,763 | 0.00 | 3,078,577 |
20 Jan 25 | Kristian Reich | Sale back to company | Dispose D | No | No | 0 | 111,949 | 0.00 | 84,367 | |
20 Jan 25 | Kristian Reich | Class A ordinary shares, par value $0.0001 per share | Conversion | Acquire C | No | No | 0 | 111,949 | 0.00 | 153,930 |
20 Jan 25 | Kristian Reich | Class A ordinary shares, par value $0.0001 per share | Conversion | Dispose C | No | No | 0 | 3,328 | 0.00 | 2,508 |
4 Oct 24 | Simon Sturge | Class A ordinary shares, par value $0.0001 per share | Sell | Dispose S | No | No | 53.72 | 171,000 | 9.19 mm | 171,980 |